Quick Answer
Immunome Inc. reported Net Income of -$212.39 million for fiscal year 2025.
Immunome Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$212.39M | +27.5% |
| 2024 | -$292.96M | -174.3% |
| 2023 | -$106.81M | -189.5% |
| 2022 | -$36.90M | -49.3% |
| 2021 | -$24.71M | -38.5% |
| 2020 | -$17.84M | -70.8% |
| 2019 | -$10.44M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$57.46M | -22.0% | -32.4% |
| June 30, 2025 | -$43.40M | -20.1% | -4.2% |
| March 31, 2025 | -$41.64M | +67.8% | +11.6% |
| September 30, 2024 | -$47.10M | -984.0% | -30.4% |
| June 30, 2024 | -$36.12M | -550.0% | +72.1% |
| March 31, 2024 | -$129.49M | -2932.6% | -2880.3% |
| September 30, 2023 | -$4.34M | +49.1% | +21.8% |
| June 30, 2023 | -$5.56M | +37.7% | -30.1% |
- Immunome Inc. showed an increase of +27.5% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Immunome Inc.’s net income has declined by 1933.6% (from -$10.44 million to -$212.39 million).
- The most recent figure is from Immunome Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: